SCHEMBL3009372

SCHEMBL3009372

O=S(=O)(c1ccc(F)c(Cl)c1)C1CCN(c2nc(Cc3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.37
DRD2 P14416 3/20 0.37
HTR2C P28335 2/20 0.37
KCNH2 Q12809 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
EPHX2 P34913 1/20 0.35
CYP19A1 P11511 1/20 0.34
HTR7 P34969 2/20 0.33
HTR6 P50406 2/20 0.33
CTSS P25774 3/20 0.32
GAA P10253 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
METAP2 P50579 3/20 0.32
MAPT P10636 3/20 0.32
USP2 O75604 1/20 0.32
RECQL P46063 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008184 0.96 HTR2A (0.38) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3008157 0.96 HTR2A (0.37) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3009964 0.95 L3MBTL1 (0.35) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3011143 0.92 HTR2A (0.43) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3012543 0.92 HTR2A (0.41) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3009255 0.91 HTR2A (0.37) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3008584 0.91 DRD2 (0.34) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3018344 0.90 HTR2A (0.41) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3011666 0.90 L3MBTL1 (0.37) HTR2ADRD2HTR2CKCNH2SMN1; SMN2
SCHEMBL3006901 0.89 GBA1 (0.39) HTR2ADRD2HTR2CKCNH2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885DRD2 573/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.